Hyaluronidase-1 (HYAL1)

Hyaluronidase-1 (HYAL1) is a **lysosomal glycoside hydrolase**—the principal hyaluronidase of human plasma—responsible for the **degradation of hyaluronan**, a major extracellular matrix glycosaminoglycan. HYAL1 cleaves the β1→4 glycosidic bond between N-acetylglucosamine and glucuronic acid units within hyaluronan, thus producing shorter oligosaccharide fragments[1][3][4]. This process regulates tissue remodeling, cell migration, proliferation, and differentiation. HYAL1 is primarily active at acidic pH, reflecting its lysosomal localization. Mutations in HYAL1 are associated with mucopolysaccharidosis type IX (a lysosomal storage disorder), and increased HYAL1 expression is commonly observed in various cancers, particularly bladder and prostate carcinomas, where it has been linked to tumor progression, invasion, and angiogenesis[2][4][6]. Multiple splice variants of HYAL1 exist, some of which have distinct roles in tumor suppression and regulation of angiogenesis. HYAL1 thus represents both a diagnostic/prognostic biomarker and a therapeutic target, although specific clinical inhibitors remain under development.

Other names

LUCA1Hyal-1Hyaluronoglucosaminidase-1Lung carcinoma protein 1plasma hyaluronidasetumor suppressor LUCA-1NAT6MPS9hyaluronidase-1hyaluronoglucosaminidase 1LuCa-1lung carcinoma protein 1

Inhibition: Drugs or compounds that inhibit HYAL1 reduce hyaluronan degradation, potentially diminishing tumor cell migration and proliferation by stabilizing extracellular matrix components. Activation/Upregulation: Increased HYAL1 activity may support tumor invasion and angiogenesis due to enhanced hyaluronan breakdown, promoting cell migration and new blood vessel formation[2][6].